Kintara Therapeutics Files 8-K on Security Holder Vote

TL;DR

KINTara is having a shareholder vote, details TBD.

AI Summary

Kintara Therapeutics, Inc. filed an 8-K on October 4, 2024, to report on the submission of matters to a vote of its security holders. The filing does not provide details on the specific matters to be voted on or the outcome of any vote.

Why It Matters

This filing indicates that Kintara Therapeutics is seeking or has sought approval from its shareholders on certain corporate matters, which could impact the company's future direction or governance.

Risk Assessment

Risk Level: medium — The filing is a procedural 8-K regarding a shareholder vote, which could have significant implications for the company's strategic decisions or financial structure, but lacks specific details.

Key Numbers

• 0630 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

• Kintara Therapeutics, Inc. (company) — Registrant
• DelMar Pharmaceuticals, Inc. (company) — Former company name
• Berry Only Inc. (company) — Former company name
• 001-37823 (company) — SEC File Number
• 99-0360497 (company) — IRS Employer Identification No.

FAQ

Filing Documents

• ktra-20241004.htm (8-K) — 99KB
• 0000950170-24-112899.txt ( ) — 220KB
• ktra-20241004.xsd (EX-101.SCH) — 27KB
• ktra-20241004_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 20, 2024, Kintara Therapeutics, Inc. (" Kintara ") convened and adjourned its 2024 Special Meeting of Stockholders (the " Special Meeting ") to October 4, 2024. On October 4, 2024, Kintara reconvened the Special Meeting being held to consider and vote on the following proposals: (a) the proposal to approve the issuance of shares of common stock of Kintara (the " Common Stock ") (such shares, the " Merger Shares ") issuable in connection with the Agreement and Plan of Merger, dated as of April 2, 2024 (the " Merger Agreement "), by and among Kintara, TuHURA Biosciences, Inc. (" TuHURA ") and Kayak Mergeco, Inc. (" Merger Sub ") (the " Nasdaq Proposal "); (b) the proposal to approve, pursuant to Nevada Revised Statutes 78.2055, a reverse stock split of only the outstanding shares of Kintara's Common Stock and other outstanding securities of Kintara (with no change to the authorized capital stock of Kintara) at a ratio ranging from 1-for-20 to 1-for-40, with such ratio to be determined in the discretion of Kintara's board of directors and with such reverse stock split to be effected at such time and date as determined by Kintara's board of directors in its sole discretion (the " Reverse Stock Split Proposal "); (c) the proposal to approve an increase in the number of authorized shares of Kintara's Common Stock to 400,000,000, to be effected at such time and date as determined by Kintara's board of directors in its sole discretion (the " Charter Proposal "); (d) the proposal to approve the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan, which was approved by Kintara's board of directors on August 7, 2024 subject to stockholder approval at the Special Meeting and upon consummation of the merger of Merger Sub with and into TuHURA (the " Merger "), with TuHURA surviving the Merger as a wholly-owned subsidiary of Kintara (the " 2024 Equity Plan Proposal "); (e) the pr

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements based upon Kintara's and TuHURA's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. These statements are only predictions. Kintara and TuHURA have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of Kintara's and TuHURA's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the risk that the conditions to the closing or consummation of the proposed Merger are not satisfied; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Kintara and TuHURA to consummate the transactions contemplated by the proposed Merger; (iii) risks related to Kintara's and TuHURA's ability to correctly estimate their respective operating expenses and expenses associated with the proposed Merger, as applicable, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company's cash resources; (iv) the occurrence of any event, change or other circumstance or condition that could g

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINTARA THERAPEUTICS, INC. Date: October 4, 2024 By: /s/ Robert E. Hoffman Name: Robert E. Hoffman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR